loading
Schlusskurs vom Vortag:
$40.56
Offen:
$40.53
24-Stunden-Volumen:
237.49K
Relative Volume:
0.41
Marktkapitalisierung:
$2.30B
Einnahmen:
$32.87M
Nettoeinkommen (Verlust:
$674.31M
KGV:
3.493
EPS:
11.36
Netto-Cashflow:
$-330.11M
1W Leistung:
-1.66%
1M Leistung:
+18.73%
6M Leistung:
+15.15%
1J Leistung:
-17.66%
1-Tages-Spanne:
Value
$39.22
$40.98
1-Wochen-Bereich:
Value
$38.48
$41.19
52-Wochen-Spanne:
Value
$23.41
$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name
Firmenname
Agios Pharmaceuticals Inc
Name
Telefon
617-649-8600
Name
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Name
Mitarbeiter
488
Name
Twitter
@AgiosPharma
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
AGIO's Discussions on Twitter

Vergleichen Sie AGIO mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
AGIO
Agios Pharmaceuticals Inc
39.68 2.30B 32.87M 674.31M -330.11M 11.36
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.50 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.19 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
588.61 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.06 31.99B 3.81B -644.79M -669.77M -6.24

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-02-24 Eingeleitet H.C. Wainwright Buy
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-10-10 Fortgesetzt Raymond James Outperform
2024-09-27 Herabstufung Leerink Partners Outperform → Market Perform
2024-02-08 Eingeleitet Cantor Fitzgerald Overweight
2023-02-03 Eingeleitet Piper Sandler Overweight
2022-11-17 Hochstufung Goldman Sell → Neutral
2022-07-27 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-12-03 Eingeleitet BofA Securities Buy
2021-07-30 Herabstufung Goldman Neutral → Sell
2021-07-01 Eingeleitet Raymond James Mkt Perform
2021-06-10 Eingeleitet H.C. Wainwright Buy
2021-03-01 Herabstufung JP Morgan Overweight → Neutral
2021-03-01 Hochstufung SVB Leerink Mkt Perform → Outperform
2021-02-26 Herabstufung SVB Leerink Outperform → Mkt Perform
2020-10-22 Hochstufung Barclays Equal Weight → Overweight
2020-03-04 Eingeleitet Barclays Equal Weight
2019-11-26 Eingeleitet Cantor Fitzgerald Overweight
2019-09-23 Hochstufung Guggenheim Neutral → Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-02-15 Hochstufung SVB Leerink Mkt Perform → Outperform
2018-09-25 Eingeleitet Leerink Partners Mkt Perform
2018-05-23 Eingeleitet Citigroup Buy
2018-04-11 Bestätigt Credit Suisse Outperform
2018-02-15 Bestätigt Needham Buy
2018-02-15 Bestätigt SunTrust Buy
2017-09-15 Eingeleitet RBC Capital Mkts Outperform
2017-08-10 Bestätigt Needham Buy
2017-08-08 Bestätigt SunTrust Buy
2017-08-02 Hochstufung Leerink Partners Mkt Perform → Outperform
2017-06-26 Herabstufung Janney Buy → Neutral
2017-01-17 Hochstufung Oppenheimer Perform → Outperform
2016-10-24 Eingeleitet Needham Buy
2016-06-13 Hochstufung JP Morgan Neutral → Overweight
2016-05-18 Bestätigt SunTrust Buy
Alle ansehen

Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten

pulisher
Jul 23, 2025

What drives Agios Pharmaceuticals Inc. stock priceTriple-digit returns - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Agios Pharmaceuticals Inc. stockFree Consultation - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is Agios Pharmaceuticals Inc. a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree AI-Backed Trading Signals - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus

Jul 22, 2025
pulisher
Jul 21, 2025

Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN

Jul 21, 2025
pulisher
Jul 18, 2025

What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser

Jul 18, 2025
pulisher
Jul 18, 2025

Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Jul 18, 2025
pulisher
Jul 15, 2025

why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq

Jul 14, 2025
pulisher
Jul 14, 2025

Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan

Jul 14, 2025
pulisher
Jul 14, 2025

Public market insider buying at Extendicare (EXE) - The Globe and Mail

Jul 14, 2025
pulisher
Jul 14, 2025

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World

Jul 14, 2025
pulisher
Jul 14, 2025

Trend Tracker for (AGIO) - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 11, 2025

Agios pharma chief medical officer Gheuens sells $452,601 in stock By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 09, 2025

Agios Pharmaceuticals Inc. (AGIO) Shares Soar 7.69% on FDA Designation - AInvest

Jul 09, 2025
pulisher
Jul 09, 2025

Agios Pharma Appoints Dr. Jay Backstrom as Director - The Globe and Mail

Jul 09, 2025
pulisher
Jul 09, 2025

Agios Pharmaceuticals appoints Jay Backstrom to board of directors By Investing.com - Investing.com South Africa

Jul 09, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors. - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom To Board - citybiz

Jul 08, 2025
pulisher
Jul 08, 2025

Agios appoints Dr. Jay Backstrom to board of directors - MarketScreener

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom to Board of Directors - The Manila Times

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals Appoints Dr. Jay Backstrom to Board of Directors - Quiver Quantitative

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Appoints Dr. Jay Backstrom to Board of Directors | AGIO St - GuruFocus

Jul 08, 2025
pulisher
Jul 08, 2025

Agios Pharmaceuticals appoints Jay Backstrom to board of directors - Investing.com India

Jul 08, 2025
pulisher
Jul 07, 2025

H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN

Jul 07, 2025
pulisher
Jun 30, 2025

Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Defensive Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Agios pharma chief legal officer Burns sells $93k in stock - Investing.com

Jun 26, 2025
pulisher
Jun 18, 2025

Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN

Jun 18, 2025
pulisher
Jun 18, 2025

Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks

Jun 18, 2025
pulisher
Jun 17, 2025

Agios' PYRUKYND Faces FDA Review In SeptemberExpansion Opportunity Ahead? - RTTNews

Jun 17, 2025
pulisher
Jun 16, 2025

10 Best NASDAQ Stocks Under $50 to Buy - Insider Monkey

Jun 16, 2025
pulisher
Jun 16, 2025

TD Cowen reiterates buy rating on Agios stock ahead of key trial data - Investing.com Canada

Jun 16, 2025
pulisher
Jun 16, 2025

Agios Pharmaceuticals Sees Shift in Fund Positioning Russell 1000 - Kalkine Media

Jun 16, 2025

Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Agios Pharmaceuticals Inc-Aktie (AGIO) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Scadden David
Director
Jul 10 '25
Sale
40.00
1,400
56,000
17,603
Gheuens Sarah
Chief Medical Officer
Jul 09 '25
Option Exercise
25.01
11,914
297,969
73,185
Gheuens Sarah
Chief Medical Officer
Jul 09 '25
Sale
37.99
11,914
452,601
61,271
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$113.95
price down icon 0.57%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):